by Isogenica Webmaster | Mar 2026 | Blogs
Machine Learning and Artificial Intelligence in Antibody Discovery: Breakthroughs, Blind Spots, and the Road Ahead To date, Machine Learning (ML) has proved itself as a powerful tool in improving the workflow and timelines of antibody discovery— for instance, ranking,...
by Isogenica Webmaster | Jan 2026 | Blogs
How VHHs Can Redefine the Next Generation of ADCs Introduction Antibody–drug conjugates (ADCs) have transformed oncology by combining the specificity of antibodies with the potency of cytotoxic payloads. Over time, ADCs have improved greatly, evolving from...
by Isogenica Webmaster | Jan 2026 | Blogs
The Proteins We Work With: A Guide to Supported Antigen Materials Introduction In the pursuit of new therapeutics, discovery teams encounter a huge variety of target proteins – from simple soluble enzymes to complex multi-pass receptors. Many of these targets...
by Isogenica Webmaster | Nov 2025 | Blogs
Building Smarter Therapeutics with VHH Bolt-Ons Single-domain antibodies derived from camelids, also known as VHHs or nanobodies, are highly adaptable binding domains widely used in protein engineering. They were pioneered by Raymond Hamers at Vrije Universiteit...
by Isogenica Webmaster | Oct 2025 | Blogs
CIS Display™ vs. Phage Display: Choosing the Right Fit for VHH or Peptide Discovery Choosing the right display technology is a critical decision in therapeutic and diagnostic discovery procedures. This article compares CIS Display™ with Phage Display, focusing on...
by Isogenica Webmaster | Sep 2025 | Blogs
NGS in Antibody Discovery: How Deep is Your Sequence? Next-generation sequencing (NGS) has revolutionized antibody discovery by enabling high-depth analysis of diverse libraries, surpassing the limitations of traditional methods like Sanger sequencing. This article...